Publisher highlighting Alzheimer's Disease Awareness and Caregivers Month with five other new neurological disease titles and a sixth coming in 2017
CAMBRIDGE, MA--(Marketwired - November 01, 2016) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease, edited by Adeboye Adejare. The book aims to improve drug discovery and development for neurodegenerative disorders by focusing on current knowledge and strategies in Alzheimer's disease (AD). Also in recognition of Alzheimer's Disease Awareness and Caregivers Month, Elsevier has published five additional titles on Alzheimer's and other neurological diseases, with a sixth slated for publication in March 2017.
Exploring diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more, Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease is a valuable resource for all pharmaceutical scientists, pharmacologists, neuroscientists and clinical researchers working in this area. The book illustrates why some drugs tend to fail at the clinical stage, and examines AD within the overall context of improving the drug discovery process for the treatment of other neurodegenerative disorders.
Learn why we need new therapies for neurodegenerative disorders in this sample chapter.
Dr. Adeboye Adejare is a professor of Pharmaceutical Sciences at Philadelphia College of Pharmacy, University of the Sciences, in Philadelphia, PA. His group is interested in the areas of design and synthesis of small organic molecules to probe neurodegeneration; in vitro models of drug absorption and ability to cross blood brain barrier; drug targeting; pharmaceutical profiling; and chemistry of fluoroaromatic compounds. It focuses on the major therapeutic areas of N-methyl-D-aspartate (NMDA) receptor antagonists and gamma-secretase inhibitors, two mechanisms implicated in neurodegeneration as observed in AD and stroke.
The seven new neurological diseases titles are:
In order to meet content needs in the neurological sciences, Elsevier uses proprietary tools to identify the gaps in coverage of the topics. Editorial teams strategically fill those gaps with content written by key influencers in the field, giving students, faculty and researchers the content they need to answer challenging questions and improve outcomes. These new books, which will educate the next generation of neurologists and AD researchers, and provide critical foundational content for information professionals, are key examples of how Elsevier is enabling science to drive innovation.
Note for Editors
E-book review copies of the new books are available to credentialed journalists upon request. Contact Jelena Baras at email@example.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey -- and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com
Publicity Team, Science & Technology Books, Elsevier